JAMA neurology最新文献

{"title":"Somebody to Love.","authors":"Victoria Johnson","doi":"10.1001/jamaneurol.2025.1382","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.1382","url":null,"abstract":"","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":" ","pages":""},"PeriodicalIF":20.4,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Parkinson Disease in Individuals With Autism Spectrum Disorder.","authors":"Weiyao Yin,Abraham Reichenberg,Michal Schnaider Beeri,Stephen Z Levine,Jonas F Ludvigsson,Martijn Figee,Sven Sandin","doi":"10.1001/jamaneurol.2025.1284","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.1284","url":null,"abstract":"ImportanceRecent research suggests a plausible biological link between autism spectrum disorder (ASD) and Parkinson disease (PD). Nonetheless, large longitudinal studies examining the risk of PD following ASD are lacking.ObjectiveTo examine the association between ASD and future PD risk.Design, Setting, and ParticipantsA nationwide population-based prospective cohort study was performed using data from Swedish national registers. All individuals born in Sweden from 1974 to 1999 with follow-up from age 20 years until December 31, 2022, and with complete covariate data were included. The analysis was completed in August 2024.ExposuresDiagnoses of ASD as a time-varying exposure obtained from the National Patient Register.Main Outcomes and MeasuresDiagnoses of PD were obtained from the National Patient Register through 2022. The relative risk (RR) of PD was quantified using incidence rate ratios with 95% CIs from Poisson regression. Preterm birth, depression, antidepressant use, and antipsychotic exposure over time were potentially modifying life events.ResultsThe study included 2 278 565 individuals (median [IQR] age at exit, 34 [29-42] years; 1 106 772 female [48.6%]), contributing 33 858 476 person-years. PD occurred in 438 of 2 226 611 individuals without ASD (0.02%; 1.3 cases/100 000 person-years) and 24 of 51 954 individuals with ASD (0.05%; 3.9 cases/100 000 person-years) (RR, 4.43 [95% CI, 2.92-6.72]). The risk estimates were similar after adjusting for sex, socioeconomic status, family history of mental illness, family history of PD, and age at ASD diagnosis. Preterm or early-term birth was not associated with and did not modify the PD risk. Depression and antidepressant use (present in 24 257 individuals with ASD [46.7%]) were associated with increased risk of PD (RR, 2.01 [95% CI, 1.40-2.88]), independent of ASD. Antipsychotic exposure (present in 16 387 individuals with ASD [31.5%]) reduced but did not fully attenuate the association (RR, 2.00 [95% CI, 1.27-3.14]) and showed no interaction with ASD on PD risk.Conclusions and RelevanceASD was associated with increased risk of PD, even after adjusting for depression or antidepressant use and antipsychotic exposure. These findings suggest a potential shared etiology between neurodevelopmental disorders and PD, and a heightened awareness of long-term neurological conditions in individuals with ASD may be warranted.","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"146 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144146170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spontaneous Intracranial Hypotension Due to Cerebrospinal Fluid Rhinorrhea.","authors":"Wouter I Schievink,Marcel M Maya,William H Slattery","doi":"10.1001/jamaneurol.2025.1387","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.1387","url":null,"abstract":"","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"1 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144146171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage: The Global Burden of Disease Study 2021.","authors":",Ilari Rautalin,Victor Volovici,Benjamin A Stark,Catherine O Johnson,Jaakko Kaprio,Miikka Korja,Rita V Krishnamurthi,Balakrishnan Sukumaran Nair,Annemarei Ranta,Gabriel J E Rinkel,Mervyn D I Vergouwen,Yohannes Habtegiorgis Abate,Hedayat Abbastabar,Foad Abd-Allah,Atef Abdelkader,Parsa Abdi,Arash Abdollahi,Auwal Abdullahi,Olugbenga Olusola Abiodun,Richard Gyan Aboagye,Mohamed Abouzid,Dariush Abtahi,Samir Abu Rumeileh,Ahmed Abualhasan,Hasan Abualruz,Hana J Abukhadijah,Ahmed Abu-Zaid,Lawan Hassan Adamu,Isaac Yeboah Addo,Rufus Adesoji Adedoyin,Oyelola A Adegboye,Saryia Adra,Leticia Akua Adzigbli,Williams Agyemang-Duah,Bright Opoku Ahinkorah,Aqeel Ahmad,Danish Ahmad,Amir Mahmoud Ahmadzade,Ali Ahmed,Haroon Ahmed,Syed Anees Ahmed,Budi Aji,Mohammed Ahmed Akkaif,Yazan Al-Ajlouni,Ziyad Al-Aly,Mohammed Albashtawy,Mohammed Usman Ali,Sheikh Mohammad Alif,Yousef Alimohamadi,Syed Mohamed Aljunid,Mahmoud A Alomari,Ahmad Alrawashdeh,Mohammed A Alsabri,Rustam Al-Shahi Salman,Awais Altaf,Alaa B Al-Tammemi,Nelson Alvis-Guzman,Hassan Alwafi,Mohammad Al-Wardat,Yaser Mohammed Al-Worafi,Hany Aly,Mohammad Sharif Ibrahim Alyahya,Karem H Alzoubi,Reza Amani,Tarek Tawfik Amin,Alireza Amindarolzarbi,Ganiyu Adeniyi Amusa,Deanna Anderlini,Dhanalakshmi Angappan,Abhishek Anil,Boluwatife Stephen Anuoluwa,Saleha Anwar,Anayochukwu Edward Anyasodor,Geminn Louis Carace Apostol,Jalal Arabloo,Demelash Areda,Johan Ärnlöv,Anton A Artamonov,Kurnia Dwi Artanti,Ashokan Arumugam,Zahra Aryan,Mohammad Asghari-Jafarabadi,Mubarek Yesse Ashemo,Tahira Ashraf,Mohammad Athar,Seyyed Shamsadin Athari,Avinash Aujayeb,Adedapo Wasiu Awotidebe,Sina Azadnajafabad,Shahkaar Aziz,Ahmed Y Azzam,Giridhara Rathnaiah Babu,Nasser Bagheri,Pegah Bahrami Taghanaki,Saeed Bahramian,Ruhai Bai,Atif Amin Baig,Abdulaziz T Bako,Ovidiu Constantin Baltatu,Kiran Bam,Maciej Banach,Soham Bandyopadhyay,Biswajit Banik,Mainak Bardhan,Suzanne Lyn Barker-Collo,Till Winfried Bärnighausen,Hiba Jawdat Barqawi,Lingkan Barua,Mohammad-Mahdi Bastan,Sanjay Basu,Shelly L Bell,Isabela M Bensenor,Alemshet Yirga Berhie,Kebede A Beyene,Akshaya Srikanth Bhagavathula,Sonu Bhaskar,Ajay Nagesh Bhat,Vivek Bhat,Gurjit Kaur Bhatti,Jasvinder Singh Bhatti,Ali Bijani,Boris Bikbov,Mekuriaw Mesfin Birhan,Mulugeta M Birhanu,Veera R Bitra,Archith Boloor,Hamed Borhany,Susanne Breitner,Hermann Brenner,Raffaele Bugiardini,Norma B Bulamu,Zahid A Butt,Lucas Scotta Cabral,Florentino Luciano Caetano Dos Santos,Daniela Calina,Luis Alberto Cámera,Luciana Aparecida Campos,Ismael Campos-Nonato,Angelo Capodici,Felix Carvalho,Carlos A Castañeda-Orjuela,Alberico L Catapano,Luca Cegolon,Joshua Chadwick,Chiranjib Chakraborty,Promit Ananyo Chakraborty,Sandip Chakraborty,Rama Mohan Chandika,Gashaw Sisay Chanie,Vijay Kumar Chattu,Anis Ahmad Chaudhary,Gerald Chi,Fatemeh Chichagi,Patrick R Ching,Hitesh Chopra,Sonali Gajanan Choudhari,Enayet Karim Chowdhury,Dinh-Toi Chu,Sheng-Chia Chung,Alyssa Columbus,Michael H Criqui,Alanna Gomes da Silva,Mohammad Amin Dabbagh Ohadi,Omid Dadras,Xiaochen Dai,Koustuv Dalal,Lachlan L Dalli,Emanuele D'Amico,Mohsen Dashti,Kairat Davletov,Vanessa De la Cruz-Góngora,Shayom Debopadhaya,Ivan Delgado-Enciso,Emina Derviševic,Vinoth Gnana Chellaiyan Devanbu,Syed Masudur Rahman Dewan,Amol S Dhane,Mahmoud Dibas,Thanh Chi Do,Thao Huynh Phuong Do,Sushil Dohare,Mohamed Fahmy Doheim,Klara Georgieva Dokova,Deepa Dongarwar,Mario D'Oria,Ojas Prakashbhai Doshi,Rajkumar Prakashbhai Doshi,Robert Kokou Dowou,Haneil Larson Dsouza,Siddhartha Dutta,Arkadiusz Marian Dziedzic,Abdel Rahman E'mar,David Edvardsson,Defi Efendi,Ferry Efendi,Nevine El Nahas,Islam Y Elgendy,Muhammed Elhadi,Chadi Eltaha,Mohd Elmagzoub Eltahir,Theophilus I Emeto,Natalia Fabin,Adeniyi Francis Fagbamigbe,Ayesha Fahim,Ildar Ravisovich Fakhradiyev,Jawad Fares,Pawan Sirwan Faris,Nelsensius Klau Fauk,Timur Fazylov,Ginenus Fekadu,Nuno Ferreira,Getahun Fetensa,Florian Fischer,Matteo Foschi,Ni Kadek Yuni Fridayani,Abduzhappar Gaipov,Avi A Gajjar,Aravind P Gandhi,Balasankar Ganesan,Ravindra Kumar Garg,Miglas Welay Gebregergis,Mesfin Gebrehiwot,Teferi Gebru Gebremeskel,Molla Getie,Delaram J Ghadimi,Fataneh Ghadirian,Sulmaz Ghahramani,Afsaneh Ghasemzadeh,Ramy Mohamed Ghazy,Maryam Gholamalizadeh,Sherief Ghozy,Artyom Urievich Gil,Jaleed Ahmed Gilani,Elena V Gnedovskaya,Pouya Goleij,Alessandra C Goulart,Barbara Niegia Garcia Goulart,Shi-Yang Guan,Sapna Gupta,Farrokh Habibzadeh,Mostafa Hadei,Najah R Hadi,Samer Hamidi,Nasrin Hanifi,Graeme J Hankey,Netanja I Harlianto,Josep Maria Haro,Faizul Hasan,Hamidreza Hasani,Md Saquib Hasnain,Mahgol Sadat Hassan Zadeh Tabatabaei,Johannes Haubold,Rasmus J Havmoeller,Simon I Hay,Youssef Hbid,Golnaz Heidari,Mohammad Heidari,Mehdi Hemmati,Yuta Hiraike,Nguyen Quoc Hoan,Ramesh Holla,Mehdi Hosseinzadeh,Sorin Hostiuc,Junjie Huang,Hong-Han Huynh,Bing-Fang Hwang,Segun Emmanuel Ibitoye,Nayu Ikeda,Adalia Ikiroma,Mehran Ilaghi,Olayinka Stephen Ilesanmi,Irena M Ilic,Milena D Ilic,Md Rabiul Islam,Nahlah Elkudssiah Ismail,Hiroyasu Iso,Gaetano Isola,Masao Iwagami,Louis Jacob,Abdollah Jafarzadeh,Akhil Jain,Ammar Abdulrahman Jairoun,Mihajlo Jakovljevic,Abubakar Ibrahim Jatau,Talha Jawaid,Sathish Kumar Jayapal,Jost B Jonas,Nitin Joseph,Mikk Jürisson,Vidya Kadashetti,Rizwan Kalani,Vineet Kumar Kamal,Arun Kamireddy,Tanuj Kanchan,Himal Kandel,Jafar Karami,Ibraheem M Karaye,Yeganeh Karimi,Arman Karimi Behnagh,Faizan Zaffar Kashoo,Gbenga A Kayode,Foad Kazemi,Emmanuelle Kesse-Guyot,Yousef Saleh Khader,Inn Kynn Khaing,Fayaz Khan,Mohammad Jobair Khan,Haitham Khatatbeh,Moawiah Mohammad Khatatbeh,Hamid Reza Khayat Kashani,Khalid A Kheirallah,Feriha Fatima Khidri,Moein Khormali,Atulya Aman Khosla,Kwanghyun Kim,Yun Jin Kim,Adnan Kisa,Sezer Kisa,Mika Kivimäki,Ali-Asghar Kolahi,Farzad Kompani,Oleksii Korzh,Karel Kostev,Nikhil Kothari,Kewal Krishan,Varun Krishna,Vijay Krishnamoorthy,Mohammed Kuddus,Mukhtar Kulimbet,Setor K Kunutsor,Maria Dyah Kurniasari,Dian Kusuma,Ville Kytö,Carlo La Vecchia,Chandrakant Lahariya,Daphne Teck Ching Lai,Hanpeng Lai,Tri Laksono,Tea Lallukka,Kamaluddin Latief,Kaveh Latifinaibin,Nhi Huu Hanh Le,Thao Thi Thu Le,Munjae Lee,Seung Won Lee,Wei-Chen Lee,Yo Han Lee,Jacopo Lenzi,Matilde Leonardi,Ming-Chieh Li,Xiaopan Li,Stephen S Lim,Jialing Lin,Xuefeng Liu,Valerie Lohner,László Lorenzovici,Paulo A Lotufo,Giancarlo Lucchetti,Jay B Lusk,Ricardo Lutzky Saute,Hawraz Ibrahim M Amin,Armaan K Malhotra,Kashish Malhotra,Ahmad Azam Malik,Deborah Carvalho Malta,Mohammad Ali Mansournia,Lorenzo Giovanni Mantovani,Emmanuel Manu,Hamid Reza Marateb,Mirko Marino,Seyed Farzad Maroufi,Ramon Martinez-Piedra,Santi Martini,Miquel Martorell,Roy Rillera Marzo,Yasith Mathangasinghe,Elezebeth Mathews,Andrea Maugeri,Steven M McPhail,Asim Mehmood,Man Mohan Mehndiratta,Kamran Mehrabani-Zeinabad,Ritesh G Menezes,Sultan Ayoub Meo,Atte Meretoja,Tomislav Mestrovic,Chamila Dinushi Kukulege Mettananda,Tomasz Miazgowski,Ana Carolina Micheletti Gomide Nogueira de Sá,Giuseppe Minervini,Le Huu Nhat Minh,Andreea Mirica,Erkin M Mirrakhimov,Mohammad Mirza-Aghazadeh-Attari,Ajay Kumar Mishra,Prasanna Mithra,Abdalla Z Mohamed,Ahmed Ismail Mohamed,Ameen Mosa Mohammad,Soheil Mohammadi,Abdollah Mohammadian-Hafshejani,Shafiu Mohammed,Ali H Mokdad,Sabrina Molinaro,Shaher Momani,Mohammad Ali Moni,AmirAli Moodi Ghalibaf,Maryam Moradi,Yousef Moradi,Paula Moraga,Lidia Morawska,Ahmed Msherghi,Kavita Munjal,Christopher J L Murray,Ahamarshan Jayaraman Nagarajan,Ganesh R Naik,Soroush Najdaghi,Noureddin Nakhostin Ansari,Shumaila Nargus,Delaram Narimani Davani,Zuhair S Natto,Javaid Nauman,Vinod C Nayak,Athare Nazri-Panjaki,Ruxandra Irina Negoi,Soroush Nematollahi,Charles Richard James Newton,Duc Hoang Nguyen,Hau Thi Hien Nguyen,Hien Quang Nguyen,Phat Tuan Nguyen,Van Thanh Nguyen,Robina Khan Niazi,Yeshambel T Nigatu,Ali Nikoobar,Antonio Tolentino Nogueira de Sá,Shuhei Nomura,Jean Jacques Noubiap,Fred Nugen,Chimezie Igwegbe Nzoputam,Bogdan Oancea,Michael Safo Oduro,Tolulope R Ojo-Akosile,Hassan Okati-Aliabad,Sylvester Reuben Okeke,Akinkunmi Paul Okekunle,Andrew T Olagunju,Muideen Tunbosun Olaiya,Arão Belitardo Oliveira,Gláucia Maria Moraes Oliveira,Abdulhakeem Abayomi Olorukooba,Isaac Iyinoluwa Olufadewa,Raffaele Ornello,Esteban Ortiz-Prado,Uchechukwu Levi Osuagwu,Amel Ouyahia,Mayowa O Owolabi,Ahmad Ozair,Mahesh Padukudru P A,Alicia Padron-Monedero,Jagadish Rao Padubidri,Demosthenes Panagiotakos,Georgios D Panos,Leonidas D Panos,Ioannis Pantazopoulos,Romil R Parikh,Seoyeon Park,Jay Patel,Urvish K Patel,Dimitrios Patoulias,Paolo Pedersini,Emmanuel K Peprah,Gavin Pereira,Arokiasamy Perianayagam,Norberto Perico,Simone Perna,Fanny Emily Petermann-Rocha,Anil K Philip,Michael A Piradov,Evgenii Plotnikov,Roman V Polibin,Maarten J Postma,Jalandhar Pradhan,Manya Prasad,Jagadeesh Puvvula,Nameer Hashim Qasim,Gangzhen Qian,Alberto Raggi,Fakher Rahim,Vafa Rahimi-Movaghar,Mosiur Rahman,Muhammad Aziz Rahman,Amir Masoud Rahmani,Mohammad Rahmanian,Sathish Rajaa,Ali Rajabpour Sanati,Pushp Lata Rajpoot,Prashant Rajput,Mahmoud Mohammed Ramadan,Shakthi Kumaran Ramasamy,Sheena Ramazanu,Amey Rane,Sina Rashedi,Mohammad-Mahdi Rashidi,Devarajan Rathish,Salman Rawaf,Christian Razo,Murali Mohan Rama Krishna Reddy,Elrashdy Redwan,Giuseppe Remuzzi,Nazila Rezaei,Negar Rezaei,Mohsen Rezaeian,Hermano Alexandre Lima Rocha,Jefferson Antonio Buendia Rodriguez,Leonardo Roever,Michele Romoli,Marina Romozzi,Allen Guy Ross,Himanshu Sekhar Rout,Nitai Roy,Priyanka Roy,Aly M A Saad,Zahra Saadatian,Siamak Sabour,Simona Sacco,Basema Ahmad Saddik,Erfan Sadeghi,Usman Saeed,Fatemeh Saheb Sharif-Askari,Amirhossein Sahebkar,Pragyan Monalisa Sahoo,Md Refat Uz Zaman Sajib,Luciane B Salaroli,Mohamed A Saleh,Yoseph Leonardo Samodra,Vijaya Paul Samuel,Abdallah M Samy,Milena M Santric-Milicevic,Aswini Saravanan,Tanmay Sarkar,Gargi Sachin Sarode,Sachin C Sarode,Benn Sartorius,Maheswar Satpathy,Markus P Schlaich,Ione Jayce Ceola Schneider,Art Schuermans,Siddharthan Selvaraj,Subramanian Senthilkumaran,Sadaf G Sepanlou,Yashendra Sethi,Allen Seylani,Ahmed Nabil Shaaban,Mahan Shafie,Moyad Jamal Shahwan,Masood Ali Shaikh,Summaiya Zareen Shaikh,Muhammad Aaqib Shamim,Anas Shamsi,Alfiya Shamsutdinova,Mohd Shanawaz,Mohammed Shannawaz,Amin Sharifan,Javad Sharifi Rad,Vishal Sharma,Bereket Beyene Shashamo,Mahabalesh Shetty,Premalatha K Shetty,Mika Shigematsu,Aminu Shittu,Ivy Shiue,Nathan A Shlobin,Seyed Afshin Shorofi,Emmanuel Edwar Siddig,Baljinder Singh,Paramdeep Singh,Puneetpal Singh,Surjit Singh,Farrukh Sobia,Ranjan Solanki,Shipra Solanki,Soroush Soraneh,Michael Spartalis,Suresh Kumar Srinivasamurthy,Jeffrey D Stanaway,Muhammad Haroon Stanikzai,Antonina V Starodubova,Jing Sun,Zhong Sun,Chandan Kumar Swain,Lukasz Szarpak,Payam Tabaee Damavandi,Seyyed Mohammad Tabatabaei,Seyed-Amir Tabatabaeizadeh,Celine Tabche,Jabeen Taiba,Iman M Talaat,Jacques Lukenze Tamuzi,Ker-Kan Tan,Mohamad-Hani Temsah,Masayuki Teramoto,Ramna Thakur,Kavumpurathu Raman Thankappan,Rasiah Thayakaran,Sathish Thirunavukkarasu,Jansje Henny Vera Ticoalu,Krishna Tiwari,Marcello Tonelli,Roman Topor-Madry,Marcos Roberto Tovani-Palone,An Thien Tran,Jasmine T Tran,Thang Huu Tran,Nguyen Tran Minh Duc,Thomas Clement Truelsen,Thien Tan Tri Tai Truyen,Daniel Hsiang-Te Tsai,Atta Ullah,Brigid Unim,Bhaskaran Unnikrishnan,Carolyn Anne Unsworth,Jibrin Sammani Usman,Sanaz Vahdati,Asokan Govindaraj Vaithinathan,Rohollah Valizadeh,Jef Van den Eynde,Joe Varghese,Tommi Juhani Vasankari,Narayanaswamy Venketasubramanian,Dominique Vervoort,Jorge Hugo Villafañe,Manish Vinayak,Sergey Konstantinovitch Vladimirov,Hatem A Wafa,Yasir Waheed,Waseem Wahood,Mandaras Tariku Walde,Yanzhong Wang,Nuwan Darshana Wickramasinghe,Peter Willeit,Asrat Arja Wolde,Charles D A Wolfe,Yihun Miskir Wubie,Hong Xiao,Suowen Xu,Xiaoyue Xu,Kazumasa Yamagishi,Yuichiro Yano,Amir Yarahmadi,Habib Yaribeygi,Sanni Yaya,Pengpeng Ye,Dong Keon Yon,Naohiro Yonemoto,Chuanhua Yu,Aurora Zanghì,Iman Zare,Michael Zastrozhin,Chen Zhang,Yunquan Zhang,Zhi-Jiang Zhang,Zhiqiang Zhang,Hanqing Zhao,Shang Cheng Zhou,Abzal Zhumagaliuly,Hafsa Zia,Magdalena Zielinska,Samer H Zyoud,Gregory A Roth,Valery L Feigin","doi":"10.1001/jamaneurol.2025.1522","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.1522","url":null,"abstract":"ImportanceNontraumatic subarachnoid hemorrhage (SAH) represents the third most common stroke type with unique etiologies, risk factors, diagnostics, and treatments. Nevertheless, epidemiological studies often cluster SAH with other stroke types leaving its distinct burden estimates obscure.ObjectiveTo estimate the worldwide burden of SAH.Design, Setting, and ParticipantsBased on the repeated cross-sectional Global Burden of Disease (GBD) 2021 study, the global burden of SAH in 1990 to 2021 was estimated. Moreover, the SAH burden was compared with other diseases, and its associations with 14 individual risk factors were investigated with available data in the GBD 2021 study. The GBD study included the burden estimates of nontraumatic SAH among all ages in 204 countries and territories between 1990 and 2021.ExposuresSAH and 14 modifiable risk factors.Main Outcomes and MeasuresAbsolute numbers and age-standardized rates with 95% uncertainty intervals (UIs) of SAH incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) as well as risk factor-specific population attributable fractions (PAFs).ResultsIn 2021, the global age-standardized SAH incidence was 8.3 (95% UI, 7.3-9.5), prevalence was 92.2 (95% UI, 84.1-100.6), mortality was 4.2 (95% UI, 3.7-4.8), and DALY rate was 125.2 (95% UI, 110.5-142.6) per 100 000 people. The highest burden estimates were found in Latin America, the Caribbean, Oceania, and high-income Asia Pacific. Although the absolute number of SAH cases increased, especially in regions with a low sociodemographic index, all age-standardized burden rates decreased between 1990 and 2021: the incidence by 28.8% (95% UI, 25.7%-31.6%), prevalence by 16.1% (95% UI, 14.8%-17.7%), mortality by 56.1% (95% UI, 40.7%-64.3%), and DALY rate by 54.6% (95% UI, 42.8%-61.9%). Of 300 diseases, SAH ranked as the 36th most common cause of death and 59th most common cause of DALY in the world. Of all worldwide SAH-related DALYs, 71.6% (95% UI, 63.8%-78.6%) were associated with the 14 modeled risk factors of which high systolic blood pressure (population attributable fraction [PAF] = 51.6%; 95% UI, 38.0%-62.6%) and smoking (PAF = 14.4%; 95% UI, 12.4%-16.5%) had the highest attribution.Conclusions and RelevanceAlthough the global age-standardized burden rates of SAH more than halved over the last 3 decades, SAH remained one of the most common cardiovascular and neurological causes of death and disabilities in the world, with increasing absolute case numbers. These findings suggest evidence for the potential health benefits of proactive public health planning and resource allocation toward the prevention of SAH.","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"137 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144122261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Residual Risk of Recurrent Stroke Despite Anticoagulation in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis.","authors":"John J McCabe,Yuen Cheung,Marianne Foley,Stephen O Brennan,Jane Buckley,Pol Camps Renom,Tim Cassidy,Ronan Collins,Eamon Dolan,Gerrit M Grosse,Joseph Harbison,Kirstyn James,Kayvan Khadjooi,Isuru Induruwa,Mira Katan,Senan Maher,Margaret O'Connor,Martin O'Donnell,Francisco Purroy,Padraig Synott,Peter J Kelly","doi":"10.1001/jamaneurol.2025.1337","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.1337","url":null,"abstract":"ImportanceAtrial fibrillation (AF) is a leading cause of stroke, and oral anticoagulants (OAC) reduce this risk. However, there are limited data on the residual risk of recurrent stroke in patients with AF.ObjectiveTo determine the recurrent stroke risk in patients with AF by performing a systematic review and meta-analysis.Data SourcesEligible studies were identified by searching Ovid MEDLINE and Embase from inception (Ovid: January 1946; Embase: January 1970) until January 2025.Study SelectionEligible studies enrolled patients with prior ischemic stroke and AF, reported information on incidence of recurrent stroke, and had follow-up data for 1 or more years. Three reviewers independently screened abstracts and performed full-text reviews.Data Extraction and SynthesisData extraction was performed by 2 reviewers and independently verified by a third. Incidence rates were pooled using random-effects meta-analysis. Analysis was repeated in patients whose qualifying event occurred despite OAC. Study quality was assessed using the Quality In Prognosis Studies tool.Main Outcomes and MeasuresThe primary outcome was recurrent ischemic stroke. The secondary outcomes were any recurrent stroke (ischemic stroke or intra-cerebral hemorrhage [ICH]) and ICH during follow-up.ResultsA total of 23 studies were identified, which included 78 733 patients and 140 307 years of follow-up. The median proportion of OAC use across studies was 92%. The pooled incidence of recurrent ischemic stroke was 3.75% per year (95% CI, 3.17%-4.33%). The risk was higher in noninterventional observational cohorts (4.20% per year; 95% CI, 3.41%-4.99%) compared with randomized clinical trials (2.26% per year; 95% CI, 1.96%-2.57%) (P value for interaction <.001). The risk of any recurrent stroke was 4.88% per year (95% CI, 3.87%-5.90%), and the risk of ICH was 0.58% per year (95% CI, 0.43%-0.73%). In patients with stroke despite OAC, the risk was 7.20% per year (95% CI, 5.05%-9.34%) for ischemic stroke, 8.96% per year (95% CI, 8.25%-9.67%) for any stroke, and 1.40% per year (95% CI, 0.40%-2.40%) for ICH.Conclusions and RelevanceIn this systematic review and meta-analysis, even with modern prevention therapy, the residual recurrence risk after AF-related stroke is high, with an estimated 1 in 6 patients experiencing a recurrent ischemic stroke at 5 years. These data demonstrate an urgent need to improve our understanding of the biological processes responsible for recurrence, improve risk stratification, and develop new secondary prevention strategies after AF-related stroke.","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"45 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144103809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Eptinezumab in Episodic Cluster Headache: A Randomized Clinical Trial.","authors":"Rigmor H Jensen,Cristina Tassorelli,Stewart J Tepper,Andrew Charles,Peter J Goadsby,Agneta H Snoer,Bjørn Sperling,Mette Krog Josiassen,Christine Borgen Linander,Anders Ettrup,Neli Boneva","doi":"10.1001/jamaneurol.2025.1317","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.1317","url":null,"abstract":"ImportanceCluster headache, characterized by bouts of excruciating pain attacks, detrimentally affects health and quality of life. Eptinezumab is an anticalcitonin gene-related peptide monoclonal antibody approved for migraine prevention.ObjectiveTo evaluate the efficacy and safety of eptinezumab in the preventive treatment of episodic cluster headache.Design, Setting, and ParticipantsThis double-blind, placebo-controlled, randomized (1:1) clinical trial (Eptinezumab in Participants With Episodic Cluster Headache [ALLEVIATE]) was conducted between December 2020 and October 2023. Results are from the initial 4-week randomized phase. The study took place at 64 sites across Europe, the US, and Japan. Included were adults (aged 18-75 years) with a history of episodic cluster headache for 1 or more years (with bouts lasting ≥6 weeks when untreated) and previous acute and preventive medication use.InterventionsEptinezumab, 400 mg, or placebo (intravenous infusion).Main Outcomes and MeasuresThe primary end point was the change from baseline in the number of weekly attacks in weeks 1 to 2. Safety was assessed using treatment-emergent adverse events.ResultsOf 628 total participants screened, 320 entered the second screening period, and 231 met eligibility criteria. Of the 231 participants randomized (eptinezumab, n = 118; placebo, n = 113), 215 (93%) completed the placebo-controlled period. The participant mean (SD) age was 44 (11) years, and 178 of 229 were male (78%). At baseline, the mean (SD) weekly attacks were 15.2 (8.1) in the eptinezumab group and 15.7 (8.3) in the placebo group. There was no statistically significant difference between eptinezumab and placebo in the change from baseline in the number of weekly attacks over weeks 1 to 2 (least-squares mean [SE], -4.0 [0.93] vs -4.6 [0.89]; between-group difference, 0.7; 95% CI, -1.3 to 2.6; P = .50). More eptinezumab-treated participants achieved 50% or greater response vs placebo over week 2 (50.9% [54 of 106] vs 37.3% [41 of 110]; odds ratio [OR], 1.77; 95% CI, 1.03-3.07; P =.04), week 3 (62.5% [65 of 104] vs 43.8% [49 of 112]; OR, 2.26; 95% CI, 1.30-3.97; P =.004), and week 4 (66.7% [68 of 102] vs 50.5% [54 of 107]; OR, 2.14; 95% CI, 1.21-3.83; P =.009). Eptinezumab showed numerically larger improvements than placebo for 75% or greater response, average daily pain scores, and across other patient-reported outcomes. Treatment-emergent adverse events occurred in 25.0% of patients (28 of 112) receiving eptinezumab and 26.5% of patients (31 of 117) receiving placebo.Conclusions and RelevanceAmong adults with episodic cluster headache, eptinezumab did not significantly reduce the number of attacks vs placebo, although it was associated with numerically higher responder rates and improvements in average daily pain and patient-reported outcomes. Eptinezumab was generally well tolerated.Trial RegistrationClinicalTrials.gov Identifier: NCT04688775.","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"8 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144087748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease.","authors":"Alexa Pichet Binette, Ruben Smith, Gemma Salvadó, Pontus Tideman, Isabelle Glans, Danielle van Westen, Colin Groot, Rik Ossenkoppele, Erik Stomrud, Piero Parchi, Henrik Zetterberg, Kaj Blennow, Niklas Mattsson-Carlgren, Shorena Janelidze, Sebastian Palmqvist, Oskar Hansson","doi":"10.1001/jamaneurol.2025.1100","DOIUrl":"10.1001/jamaneurol.2025.1100","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;While clinical disease stages remained largely unchanged in the 2024 update of the Alzheimer disease (AD) criteria, tau-positron emission tomography (PET) was introduced as a core biomarker and its spatial extent was incorporated into the revised biological stages of the disease. It is important to consider both the clinical and the biological stages and understand their discrepancies.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To compare individuals who have discrepant biological and clinical stages with those who have congruent stages in terms of copathologies, comorbidities, and demographics.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;Participants were from the Swedish BioFINDER-2 (inclusion from 2017 through 2023) and the Alzheimer's Disease Neuroimaging Initiative (ADNI) (inclusion from 2015 through 2024). BioFINDER-2 included a prospective population-based (cognitively normal [CN] older adults) and memory clinic-based cohort (participants with subjective cognitive impairment [SCD], mild cognitive impairment [MCI], and dementia). ADNI included a volunteer-based sample. All participants who were amyloid-β positive and had undergone tau-PET were included. In BioFINDER-2, 838 participants of a total of 1979 were included, and of 927 with tau-PET in ADNI, 380 were included.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Exposures: &lt;/strong&gt;The clinical (CN to dementia) and biological (based on PET; initial [amyloid-β-positive only] to advanced [amyloid-β-positive, elevated, and widespread tau]) stages from the revised AD criteria.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;Cross-sectional measures of neurodegeneration (cortical thickness, TAR DNA-binding protein 43 [TDP-43] imaging signature, neurofilament light [NfL]), α-synuclein cerebrospinal fluid status, plasma glial fibrillary acidic protein, white matter lesions, infarcts, microbleeds, comorbidities, and demographics.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;There were 838 BioFINDER-2 participants (mean age, 73.9 [SD, 7.3] years; 431 women [51%]; 407 men [49%]) and 380 ADNI participants (average age, 72.9 [SD, 7.0] years; 194 women [51%]; 186 mean [49%]) included. In BioFINDER-2, 37.7% of the sample had congruent biological and clinical stages (reference group), 51.3% had more advanced clinical impairment compared with their clinical stage (clinical &gt; biological) and 11.0% had the opposite (biological &gt; clinical). The main differences were between the reference group and the clinical &gt; biological group: the latter participants were more often positive for α-synuclein pathology, had higher NfL levels, greater TDP-43-like atrophy, and higher burden of cerebral small vessel disease lesions (all false discovery rate P &lt; .05). The only difference between the biological &gt; clinical and the reference group was that the former had less neurodegeneration (thicker cortex; all false discovery rate P &lt; .001). The main results were replicated in the independent ADNI cohort, where congruent 56.1% of","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":" ","pages":""},"PeriodicalIF":20.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemorrhage Into the Canal of Gratiolet.","authors":"Noriko Nara,Ken Johkura","doi":"10.1001/jamaneurol.2025.1182","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.1182","url":null,"abstract":"","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"77 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144087776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lecanemab Treatment in a Specialty Memory Clinic.","authors":"Madeline Paczynski,Anna Hofmann,Zachary Posey,Maren Gregersen,Michelle Rudman,Dawn Ellington,Melissa Aldinger,Erik S Musiek,David M Holtzman,Randall J Bateman,Justin M Long,Nupur Ghoshal,David B Carr,Alan Dow,Sheyda Namazie-Kummer,Nayid Jana,Chengjie Xiong,John C Morris,Tammie L S Benzinger,Suzanne E Schindler,B Joy Snider","doi":"10.1001/jamaneurol.2025.1232","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.1232","url":null,"abstract":"ImportanceTwo monoclonal antibodies targeting amyloid plaques, lecanemab and donanemab, have received traditional US Food and Drug Administration (FDA) approval for the treatment of early symptomatic Alzheimer disease (AD). The most significant adverse events associated with these therapies are infusion-related reactions and amyloid-related imaging abnormalities (ARIA) with edema/effusion (ARIA-E) and/or hemorrhage/hemosiderin deposition (ARIA-H). The feasibility and safety of providing these treatments in clinical practice is unclear.ObjectiveTo examine the feasibility and safety of treating patients in specialty memory clinics with lecanemab.Design, Setting, and ParticipantsThis retrospective analysis of consecutive patients in whom lecanemab was initiated between August 1, 2023, and October 1, 2024, at Washington University Memory Diagnostic Center, an outpatient specialty memory clinic. Lecanemab was initiated in 234 patients with early symptomatic AD. Eligibility was based on the FDA label and appropriate use recommendations with occasional exceptions.ExposurePatients were treated with lecanemab, 10 mg/kg, intravenously every 2 weeks.Main Outcomes and MeasuresInfusion-related reactions, ARIA, and withdrawal from treatment were assessed.ResultsThe 234 patients treated with lecanemab had a mean age of 74.4 (SD, 6.7) years, 117 were female (50%), and 117 were male. (50%) Infusion-related reactions occurred in 87 patients (37%) and were typically mild. Of the 194 patients at risk for ARIA during the study period, 44 had at least 1 microhemorrhage and/or superficial siderosis before initiation of lecanemab (23%). Over an average treatment period of 6.5 months, 42 total patients (22%) developed ARIA; 29 developed ARIA-E with or without ARIA-H (15%) and 13 developed isolated ARIA-H (6.7%). Eleven patients (5.7%) developed symptomatic ARIA, 2 of those patients (1.0%) with clinically severe symptoms. No patients developed a macrohemorrhage or died. Patients with mild dementia had a 27% rate of symptomatic ARIA; those with mild cognitive impairment or very mild dementia had a 1.8% rate. Overall, 23 of 234 patients (9.8%) withdrew from treatment for various reasons, 10 for ARIA (4.3%).Conclusions and RelevanceA single-specialty memory clinic initiated lecanemab treatment in 234 patients over 14 months. The frequency of significant adverse events, including ARIA, was manageable. These results may inform discussions about the risks of anti-amyloid treatments.","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"13 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143932871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the Cure.","authors":"Catherine S Hwang","doi":"10.1001/jamaneurol.2025.0908","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.0908","url":null,"abstract":"","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":" ","pages":""},"PeriodicalIF":20.4,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}